TNFSF11 and neoplasm: Transcriptomic analyses upon RANKL inhibition revealed changes in tumor metabolism, immunity, adhesion, among others, with > 100 pathways (FDR < 0.25) shared between the three PDXs (Fig EV4E; Dataset EV3, Table P).